CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Spotify billionaire’s body scan startup has come to America

From TechCrunch

By Dominic-Madori Davis

October 3, 2026

Spotify billionaire’s body scan startup has come to America

Spotify billionaire’s body scan startup has come to America

Neko Health seems to be the hottest body scan in the world right now. 

The scan, co-founded by Spotify’s David Ek and Hjalmar Nilsonne, uses advanced technology to screen for issues in the blood, skin, and metabolism. The company was founded in Sweden, has raised nearly $1 billion total, and just landed in New York. It has a global waitlist already topping 300,000 people, the company says.

TechCrunch sat down with Farooq Abbasi of Preface Ventures, who invested in the company. He hopes Neko Health can be the future of preventative medicine, especially in a country like the United States, where the medical system is notoriously plagued with issues.

Abbasi contends that preventative care utilization is low in the U.S. as people have concerns about how much it costs. Currently, Neko health charges $500 for its one-hour scan, which is not covered by insurance but should qualify as an acceptable expense for those that have Health Savings Accounts. “I think preventative care and healthcare should be cheap and accessible,” Abbasi said. 

Listen on Apple Podcasts Listen on Spotify

The hope is that Neko Health can tackle some of these issues, and it’s currently eyeing an expansion across the U.S. Abbasi has been scanned twice already and, perhaps, no surprise, says he loves it. “I think there should be Neko clinics everywhere,” he said.

He says the product has grown so much since he first tried it. “In my generation one scan, it was a blood test with 15 biomarkers,” he said. “It was fifty-five this time.” 

Neko also uses advanced computer vision for its scans and Abbasi sees this as another example of how AI is improving the medical sector overall. He argues that Neko Health isn’t just another wellness fad, but something that gives people “actionable insights to make their lives better,” he said.

Neko still has a long way to go in the U.S., especially on scaling and regulatory approval. But Abbasi is an optimist; he hopes more venture dollars will pour into the right companies and doesn’t think anything is too broken to fix.

View original article on techcrunch.com

Most Recent

9 insights from ‘Private Tech Trailblazers’: Vertical AI becomes the growth engine

Private Tech Trailblazers companies pair AI with proprietary data and hardware for specific industries, from robotics and trucks to AI chips.

Oct 3, 2026

NetApp hands storage operations to AI agents, but humans still draw the boundaries

Data governance shapes how NetApp lets AI agents manage storage operations, with humans setting policy boundaries and reviewing audit trails.

Oct 2, 2026

The biggest unresolved question in AI right now, and more takeaways from Madrona’s IA40 Summit

Executives from companies such as Microsoft, Amazon, Anthropic and Stripe agreed on a lot this week about where AI is headed. But one big question was left unresolved: who keeps the relationship with the customer, and the data that comes from it, once an AI agent is in the middle? That question was

Oct 2, 2026

AI in customer experience has an orchestration problem, not an adoption problem

Every information technology leader I talk to has an artificial intelligence story about customer experience. Almost none has an outcome story. That gap is now measurable. Talkdesk Inc., in partnership with NewtonX, surveyed 252 director-level-and-above leaders in customer experience, IT, operations

Oct 2, 2026

Similar Posts

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York

The scanning and bloodwork health startup founded by Spotify's founder will officially launch in New York in about a month.

Aug 18, 2026

Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America

Watch as Neko Health Investor Farooq Abbasi joins Equity to explain the bet on preventative healthcare, competition and what comes next.

Sep 30, 2026

Y Combinator insurance tech alum Angle Health hits $2.7B valuation

Angle Health has grown to 5,000 customers and become profitable by helping small businesses get "level-funded" health insurance.

Sep 18, 2026